Skip to main content

Table 2 Mortality in patients with and without ESRD who received CABG

From: Hospital costs and prognosis in end-stage renal disease patients receiving coronary artery bypass grafting

  ESRD (N = 48) Non-ESRD (N = 96) Adjusted HR (95% CI) P value
Mortality (%) 16 (33.33) 11 (11.46) 3.55 (1.64–7.69) .001
Mortality with comorbidities (%)
 Hypertension
  Yes 12 (25.00) 10 (10.42) 2.69 (1.16–6.26) .022
  No 4 (8.33) 1 (1.04) 11.25 (1.25–101.16) .031
 Diabetes
  Yes 13 (27.08) 9 (9.38) 4.32 (1.78–10.47) .001
  No 3 (6.25) 2 (2.08) 2.93 (0.49–17.57) .240
 Myocardial infarction
  Yes 8 (16.67) 6 (6.25) 3.68 (1.28–10.64) .016
  No 8 (16.67) 6 (6.25) 3.64 (1.19–11.17) .024
 Stroke
  Yes 7 (14.58) 3 (3.13) 7.15 (1.45–5.23) .016
  No 9 (18.75) 8 (8.33) 2.78 (1.07–7.21) .035
 Congestive heart failure
  Yes 9 (18.75) 9 (9.38) 2.26 (0.87–5.87) .093
  No 7 (14.58) 2 (2.08) 10.11 (2.09–48.99) .004
 Peripheral arterial disease
  Yes 4 (8.33) 2 (2.08) 3.20 (0.59–17.51) .179
  No 12 (25.00) 9 (9.38) 3.43 (1.44–8.17) .005
 COPD
  Yes 5 (10.42) 3 (3.13) 5.50 (1.29–23.53) .021
  No 11 (22.92) 8 (8.33) 3.18 (1.28–7.93) .013
  1. For each comorbidity variable, two Cox regression models were conduct to investigate the mortality for patients having or not having the comorbid disease